Jess Savala

A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk

Rakesh R. Patel, K. Jirström, S. Linke, 2018, Clinical Cancer Research.

Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma In Situ (DCIS) of the Breast, in a Randomized Clinical Trial (SweDCIS)

F. Vicini, G. Mann, K. Sandelin, 2021, Cancers.

A Novel Biosignature Identifies Patients With DCIS With High Risk of Local Recurrence After Breast Conserving Surgery and Radiation Therapy.

F. Vicini, G. Mann, D. Dabbs, 2022, International journal of radiation oncology, biology, physics.

Analytical validation of the 7-gene biosignature for prediction of recurrence risk and radiation therapy benefit for breast ductal carcinoma in situ

D. Dabbs, C. Shah, P. Whitworth, 2023, Frontiers in Oncology.

Assessing the benefit of adjuvant endocrine therapy in patients following breast-conserving surgery with or without radiation stratified by a 7-gene predictive DCIS biosignature.

F. Vicini, B. Czerniecki, D. Dabbs, 2022, Journal of Clinical Oncology.

Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma in Situ (DCIS) of the Breast in a Randomized Clinical Trial (SweDCIS)

F. Vicini, G. Mann, K. Sandelin, 2021, Social Science Research Network.

Abstract PD15-07: PD15-07 7-gene predictive biosignature improves risk stratification for breast ductal carcinoma in situ patients compared to clinicopathologic criteria, identifying a low risk group not clinically benefiting from adjuvant radiotherapy

F. Vicini, B. Czerniecki, G. Mann, 2023, Cancer Research.